System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ahead of print

PubMed: 42171985 DOI: 10.1007/s40119-026-00451-x

A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit.

Cardiol Ther

Authors: Faouzi Addad, Walid Amara, Ahmed Bennis, Franck Boccara, M Abed Bouraghda, Mohammed Chettibi, Hinde Iraqi, Selma Siham El Khayat, Inès Khochtali, Nadia Laredj, Rachid Malek, Habib Skhiri, Aida Soufiani, Marilucy Lopez-Sublet

Affiliations

  • Heart Care Center, Medical Lake Tower, Berges du Lac 2, Tunis, Tunisia.
  • GHI Le Raincy-Montfermeil, Montfermeil, France.
  • Cardiology Department, Ibn Rochd CHU, Casablanca, Morocco.
  • Clinical Research Group 22, C2MV-Cardiovascular and Metabolic Complications Among People Living with HIV, Inserm UMR_S 938, Saint Antoine Research Center, Cardio-Metabolism and Nutrition University Hospital Institute (ICAN), Department of Cardiology, Saint Antoine Hospital AP-HP, Sorbonne University, Paris, France.
  • Cardiology Department, Omar Yacef Draa Ben Khedda Hospital, Tizi-Ouzou, Algeria.
  • Cardiology Department, Hospital-University Centre (CHU) Beni Messous, Alger, Algeria.
  • Faculty of Medicine and Pharmacy, Ibn Sina Hospital-University Centre (CHU), Rabat, Morocco.
  • Nephrology Department, UHC Ibn Rochd, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
  • Department of Endocrinology, Hospital University Monastir, Monastir, Tunisia.
  • Department of Internal Medicine, Hospital University Monastir, Monastir, Tunisia.
  • Cardiology Department, Hospital-University Centre (CHU) Oran, Oran, Algeria.
  • Department of Internal Medicine, Hospital-University Centre (CHU) SĂ©tif, SĂ©tif, Algeria.
  • Department of Nephrology and Dialysis, Hospital-University Monastir, Monastir, Tunisia.
  • AP-HP, HĂ´pital Avicenne, Centre d'Excellence EuropĂ©en en Hypertension ArtĂ©rielle, Service de MĂ©decine Interne, 125 Rue de Stalingrad, 93000, Bobigny, France. INSERM UMR942 MASCOT, Paris 13-UniversitĂ© Paris Nord, Villetaneuse, France. FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Abstract

The inaugural 2025 Cardiometabolic Summit in Saclay, France, aimed to (i) disseminate the latest research on cardiometabolic diseases (CMDs) from the Maghreb and/or Middle East and North Africa region; (ii) discuss CMD management and provide clinical practice suggestions for improving adherence and reducing clinical inertia; and (iii) suggest policy and clinical practice initiatives to improve outcomes in patients with CMDs. Cardiovascular disease (CVD) is the leading cause of death worldwide, with 80% of CVD fatalities occurring in low- and middle-income countries. This trend is mirrored in Algeria, Morocco and Tunisia, three countries in the Maghreb region. In these countries, CMDs, such as type 2 diabetes mellitus (T2DM) and hypertension, have high prevalence and are undertreated. At the Cardiometabolic Summit, attended by 110 clinicians from Algeria, Morocco and Tunisia, regional CMD epidemiology and management data were presented, along with evidence on regional research initiatives to reduce the burden of CMDs and CVD and how Ramadan fasting affects adults with T2DM. Context-specific holistic strategies to improve the management of patients with multimorbidities were reviewed, including targeting modifiable risk factors to prevent T2DM and hypertension. Two barriers to optimal CMD management were addressed: (i) poor patient treatment adherence and (ii) clinician-related therapeutic inertia, noting the latter may be a greater contributor to poor outcomes. Prescription of single-pill combinations was recommended for initial blood pressure control, and a cost-effective sulfonylurea plus a sodium-glucose cotransporter 2 inhibitor or glucagon-like peptide 1 receptor agonist (whenever feasible) was recommended for glycaemic control plus cardiorenal protection. Polypills may be appropriate where intervention for additional CMDs is required. Strategies for enhancing patient adherence and opportunities for reducing therapeutic inertia were presented. Finally, policy actions and clinical practice priorities were suggested. These steps provide a realistic path towards reducing CMD and CVD burden in the Maghreb.

MeSH

Diabetes Mellitus, Hypertension, Research, Therapeutics, Diabetes Mellitus, Type 2, Single-Pill Combination